Northrop Grumman reports Q2 results today with the Street divided on a fresh target revision, options hedging still running near its most defensive level of the year, and the stock down 3.1% on the week at $512.29.
The sharpest development today came from the analyst community, and it told two different stories simultaneously. Susquehanna slashed its price target to $655 from $785 — a $130 cut — while maintaining a Positive rating. UBS moved the other direction, lifting its target to $685 from $666 and holding at Buy. Both actions landed this morning, within hours of each other, directly ahead of the print. The broader trend over the past month has been uniformly negative: Goldman Sachs cut to $533 from $603 on July 14, TD Cowen trimmed to $580 from $680 the day before, and Citi lowered its target for the second time in two months. Every firm in that sequence kept its rating intact. The consensus target sits near $650, implying substantial upside from current levels — but as noted in previous coverage, that gap reflects targets chasing the stock lower rather than fresh conviction that NOC is materially cheap. Goldman's $533 target, barely above the current price, captures the unease most cleanly.
Options positioning remains anchored in defensive territory and has not moved materially since Tuesday. The put/call ratio is at 1.05, still more than two standard deviations above its 20-day average of 0.98. That reading has held elevated through the final days before the print, which points to investors maintaining downside protection rather than unwinding hedges as the event approaches. The 52-week high on the PCR is 1.25, so there is room for positioning to become more extreme — but the current level is already well outside the normal range for this stock.
The lending market offers no amplifying signal in either direction. Short interest at 1.6% of free float is negligible, and borrow availability is effectively unlimited — the pool is so oversupplied relative to demand that the availability reading sits at the top of the scale. Cost to borrow eased back to 0.36% on Tuesday after briefly spiking toward 0.78% on Monday; even at the intraday peak, the absolute level was trivial. There is no squeeze pressure, no shortage of supply, and no evidence of short sellers building a meaningful position ahead of results. The put-heavy options flow is investor hedging, not short-seller conviction.
On the peer comparison, the divergence that has been building all month remains intact. LMT and RTX fell less than 2% and 0.5% respectively on the week, while LHX and HII both dropped more than 4% — suggesting some broader pressure across US defense. European names told a different story: BA. gained 3% on the week and DRS added 2.5%, continuing the pattern flagged in recent notes of international defense names outperforming their US counterparts.
The EPS momentum factor scores underline the caution: 29 on the 30-day reading and 31 on the 90-day, both well below mid-range, while the forward earnings growth factor scores near the bottom of the universe. The bull case — B-21 production ramp, F/A-XX, and the Golden Dome programme — is a multi-year story. What the market wants to know today is whether space segment weakness and programme realignments have bottomed, and whether management's tone on free cash flow gives any basis for confidence in the near-term numbers without the cover of buybacks.
The print is today after market close. The conversation will centre on whether the space segment decline has stabilised, what management guides for the second half, and whether the programme execution commentary on B-21 and autonomous systems justifies the patience bulls are being asked to show.
See the live data behind this article on ORTEX.
Open NOC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
